MCM
SUPN icon

Mason Capital Management’s Supernus Pharmaceuticals SUPN Stock Holding History

Mason Capital Management’s Portfolio SUPN Stock Details SUPN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-24,663
Closed -$621K – 29
2020
Q4 		$621K Buy
+24,663
New +$531K 0.05% 13

Other funds holding SUPN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
GKIM
GW&K Investment Management Boston, Massachusetts $11.3B AUM 31.98% 1-Year Est. Return
ACM
Ashford Capital Management Wilmington, Delaware $809M AUM 35.1% 1-Year Est. Return
SIMG
Stephens Investment Management Group Houston, Texas $7.3B AUM 41.96% 1-Year Est. Return

Mason Capital Management's SUPN Position: Q1 2021 in Review

Mason Capital Management sold out of Supernus Pharmaceuticals (SUPN) in Q1 2021, closing a stake of 24,663 shares — an estimated $621K sold.

Mason Capital Management first reported a position in SUPN in Q4 2020 and held it in 1 quarter. The position peaked at $621K in Q4 2020. 224 funds tracked by Wall St. Rank hold SUPN as of Q1 2021.

  • Mason Capital Management reported no remaining Supernus Pharmaceuticals position as of Q1 2021 after selling out during the quarter.
  • Mason Capital Management sold 24,663 Supernus Pharmaceuticals shares in Q1 2021, an estimated $621K.
  • Mason Capital Management first reported a position in Supernus Pharmaceuticals in Q4 2020 and held it in 1 quarter.
  • Mason Capital Management's Supernus Pharmaceuticals position peaked at $621K in Q4 2020.
  • 224 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q1 2021.

Based on Mason Capital Management's 13F filing for Q1 2021, filed 17 May 2021.